

Oesophageal Candidiasis

Treatment for Adult Patients

For hospital patients write indication and duration on medicine chart and score off administration boxes not required

NOTES:

- Most infections will be *Candida albicans* and therefore sensitive to fluconazole. If the infection is in a patient with a different *Candida* species isolated e.g. *C. glabrata* please contact ID or Microbiology for advice.
- Oesophageal candidiasis requires systemic therapy and sometimes occurs in the absence of oropharyngeal candidiasis
- Doses stated are for non pregnant, adult patients with normal renal and hepatic function
- Some of the doses recommended are higher than those in BNF but are based on [SPCs](#) and references below
- SIGNIFICANT INTERACTIONS – with fluconazole and itraconazole
 - Check [BNF](#) or [SPCs](#) before prescribing or discuss with pharmacist
 - Fluconazole and itraconazole can both prolong QT interval
- Obese patients – discuss with pharmacist
- Prophylaxis after treatment is not recommended as promotes resistance

1st line:

FLUCONAZOLE

- 200mg daily for 14-21 days (if very severe or immunocompromised consider 400mg daily or 200mg bd (off label dosing))
- Can be given IV if oral not tolerated but change to oral as soon as possible (90% bioavailability)
- If patient <40kg or >100kg discuss dosing with pharmacist

2nd line Fluconazole refractory disease:

ITRACONAZOLE liquid (taken on empty stomach for maximum absorption – 1 hour before or 2 hours after food)

- 200mg daily or 100mg twice daily for 14 -21 days (in very severe cases 200mg twice daily for 14 days)
- Liquid is more effective than itraconazole capsules
- Up to 80% of fluconazole refractory cases will respond to itraconazole liquid
- Caution in patients with ventricular dysfunction or heart failure
- If patient <50kg or >100kg discuss dosing with pharmacist

3rd line Non responders

- **Discuss with ID or Microbiology – samples may need sent for sensitivity testing**
- **Voriconazole, posaconazole, echinocandins are options but echinocandins are associated with a higher relapse rate**

References:

[Electronic Medicines Compendium](#) accessed on 26/01/2021

[IDSA Candidiasis Guidelines](#) *Clinical Infectious Diseases*, Volume 62, Issue 4, 15 February 2016, Pages e1–e50

Comprehensive Review of Infectious Diseases 2000

Written by: AMT Jan 2021

Approved by AMG/GI Team: Feb 2021

Review: Feb 2024